University of Colorado, Cancer Center

Aurora, Colorado 84005

38 studies enrolling now · 245 studies all time

What they study most

ALK Gene Mutation, ALK Genomic Tumor Aberrations, ALK Positive Malignancies, ALK-Positive Lung Cancer, ALK-positive NSCLC, ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC, ALK-positive Non-small Cell Lung Cancer, ARID1A Gene Mutation, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adenocarcinoma of the Lung, Adenocarcinoma of the Prostate

Studies at this site

• Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression — Recruiting now
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors — Recruiting now
• A Study of BG-C477 in Participants With Advanced Solid Tumors — Recruiting now
• A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) — Recruiting now
• Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells — Recruiting now
• A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC — Recruiting now
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) — Recruiting now
• A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) — Recruiting now
• A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer — Recruiting now
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) — Recruiting now
• Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors — Recruiting now
• Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors — Recruiting now
• Relationships Between Physical Activity and Different Measures of Fatigue in Cancer Survivors — Recruiting now
• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors — Recruiting now
• Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. — Recruiting now
• A Phase 1/1b Study of IAM1363 in HER2 Cancers — Recruiting now
• A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) — Recruiting now
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer — Recruiting now
• Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer — Recruiting now
• BfedBwell INSPIRE Pilot — Recruiting now
• Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence — Recruiting now
• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy — Recruiting now
• Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus — Recruiting now
• Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements — Recruiting now
• Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates — Recruiting now
• Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma — Recruiting now
• Microbiome in Head and Neck Squamous Cell Carcinoma — Recruiting now
• Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy — Recruiting now
• Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer — Recruiting now
• Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen — Recruiting now
• A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) — Recruiting now
• Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis — Recruiting now
• Specimen Banking From Patients With Lung Cancer — Recruiting now
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors — Recruiting now
• A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer — Recruiting now
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer — Recruiting now
• MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles — Recruiting now
• CtDNA Based MRD Testing for NAC Monitoring in TNBC — Recruiting now
• Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) — Running, not enrolling
• A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer — Stopped early
• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study — Running, not enrolling
• Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer — Stopped early
• A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma — Running, not enrolling
• Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) — Running, not enrolling
• Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer — Completed
• DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) — Running, not enrolling
• Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling
• A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. — Running, not enrolling
• Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC — Running, not enrolling
• An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma — Running, not enrolling